Osteoporosis Fracture
17
3
4
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 17 trials
100.0%
+13.5% vs benchmark
29%
5 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (17)
Romosozumab Use to Build Skeletal Integrity
The Effect of Semaglutide on Bone Health
Peripheral Mononuclear Cells to Screen, Monitor and Stratify the Population at Risk of Osteoporosis and Fractures
The Construction of Bidirectional Column Study of Acute Osteoporotic Vertebral Compression Fractures
New Biomarkers and Therapeutic Targets in Osteoporosis Via Omics Technologies
Randomized Fracture Liaison Services
Development and Validation of a Postoperative Re-fracture Risk Model for Osteoporotic Spinal Fractures
Osteoporosis and Fall Prevention and Posture Correction Interventions in the Metropolitan Area
Continuation of Anti-osteoporotic Treatment 1 Year After Initial Administration
Post-fracture Medication and Mortality
Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
Evaluating Fracture Risk Assessment Tools (FRAX) From Different Regions in Central South Chinese Postmenopausal Women
Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density
Breast Cancer Women on Aromatase Inhibitors Treatment
Height Loss, Kyphosis Indicators, Bone Mineral Density and Vertebral Fractures in Chinese Postmenopausal Women
Postrual Reduction With Pillow in Osteoporotic Vertebral Fracture
Osteoporosis and Fall Prevention With Multiple Interventions in the Metropolitan Area